The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...

PADCEV (enfortumab vedotin-ejfv) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder ...

Enfortumab vedotin was given at 1.25 mg/kg on days 1 and 8 of every 3-week cycle, with no maximum number of cycles. Pembrolizumab was given at 200 mg on day 1 for up to 35 cycles.

Source Reference: Hoimes CJ, et al "Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer" J Clin Oncol 2022; DOI: 10.1200/JCO.22.01643.

Additionally, the trial met key secondary endpoints. The objective response rate was 67.7% in the pembrolizumab plus enfortumab vedotin arm compared with 44.4% in the chemotherapy arm (P <.00001).

Enfortumab vedotin plus pembrolizumab also significantly prolonged OS with a median OS of 31.5 months vs 16.1 months for chemotherapy, reducing the risk of death by 53% (HR, 0.47; 95% CI, 0.38-0. ...

“Enfortumab vedotin is the first drug, beyond chemotherapy and immunotherapy, to show a significant survival advantage in previously treated advanced urothelial cancer,” Powles said.